{'52WeekChange': 0.08924949,
 'SandP52WeekChange': None,
 'address1': '100 Spy Court',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.55,
 'askSize': 1300,
 'averageDailyVolume10Day': 217525,
 'averageVolume': 1045680,
 'averageVolume10days': 217525,
 'beta': None,
 'beta3Year': None,
 'bid': 5.2,
 'bidSize': 1000,
 'bookValue': 0.564,
 'category': None,
 'circulatingSupply': None,
 'city': 'Markham',
 'companyOfficers': [],
 'country': 'Canada',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.38,
 'dayLow': 5.14,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.216,
 'enterpriseToRevenue': 51.248,
 'enterpriseValue': 39263136,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.9245715,
 'fiftyTwoWeekHigh': 10,
 'fiftyTwoWeekLow': 1.58,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 2706384,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 10,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.4677,
 'heldPercentInstitutions': 0.2489,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1569801600,
 'lastMarket': None,
 'lastSplitDate': 1560124800,
 'lastSplitFactor': '1:6',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/edesabiotech.com',
 'longBusinessSummary': 'Edesa Biotech, Inc., a clinical-stage '
                        'biopharmaceutical company, engages in the development '
                        'and advancement of treatments for dermatological and '
                        'gastrointestinal indications. Its lead product '
                        'candidate is EB01, a non-steroidal anti-inflammatory '
                        'molecule to treat chronic allergic contact '
                        'dermatitis. Edesa Biotech, Inc. has a collaborative '
                        'research project with the National Research Council '
                        'of Canada to develop novel immunotherapies for '
                        'vitiligo, as well as other indications; and Light '
                        'Chain Bioscience for the development and '
                        'commercialization of two Phase 2-ready biologic drug '
                        'candidates for various therapeutic, prophylactic, and '
                        'diagnostic applications. The company was founded in '
                        '2015 and is headquartered in Markham, Canada.',
 'longName': 'Edesa Biotech, Inc.',
 'market': 'us_market',
 'marketCap': 46067632,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_313039720',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -5392601,
 'nextFiscalYearEnd': 1632960000,
 'open': 5.33,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '289 800 9600',
 'previousClose': 5.37,
 'priceHint': 2,
 'priceToBook': 9.219857,
 'priceToSalesTrailing12Months': 60.129288,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.38,
 'regularMarketDayLow': 5.14,
 'regularMarketOpen': 5.33,
 'regularMarketPreviousClose': 5.37,
 'regularMarketPrice': 5.33,
 'regularMarketVolume': 53470,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 8859160,
 'sharesPercentSharesOut': 0.0084,
 'sharesShort': 74395,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 13814,
 'shortName': 'Edesa Biotech, Inc.',
 'shortPercentOfFloat': 0.0189,
 'shortRatio': 0.03,
 'startDate': None,
 'state': 'ON',
 'strikePrice': None,
 'symbol': 'EDSA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.726,
 'twoHundredDayAverage': 3.3098562,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'feae63c9-ecbf-391a-bfe7-79648f666a2a',
 'volume': 53470,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://edesabiotech.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'L3R 5H6'}